T1	DISO 107 126	esclerosis múltiple
#1	AnnotatorNotes T1	C0026769; Multiple Sclerosis; Disease or Syndrome
T2	PROC 170 275	Estudio de Fase II, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo
T3	PROC 1044 1052	tratados
#2	AnnotatorNotes T3	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T4	PROC 331 362	evaluar la eficacia y seguridad
#3	AnnotatorNotes T4	C0511730; Identify product efficacy and safety issues; Health Care Activity
T5	CHEM 374 385	secukinumab
#4	AnnotatorNotes T5	C3179547; secukinumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T6	DISO 404 423	esclerosis múltiple
#5	AnnotatorNotes T6	C0026769; Multiple Sclerosis; Disease or Syndrome
T7	DISO 469 488	Esclerosis multiple
#6	AnnotatorNotes T7	C0026769; Multiple Sclerosis; Disease or Syndrome
T8	DISO 526 566	Esclerosis Multiple Remitente Recurrente
T9	PROC 595 606	Diagnostico
#7	AnnotatorNotes T9	C0011900; Diagnosis; Diagnostic Procedure
T10	CHEM 1141 1156	interferon-beta
#8	AnnotatorNotes T10	C0015980; interferon-beta; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T11	DISO 691 701	enfermedad
#9	AnnotatorNotes T11	C0012634; Disease; Disease or Syndrome
T12	DISO 719 729	enfermedad
#10	AnnotatorNotes T12	C0012634; Disease; Disease or Syndrome
T13	PROC 801 810	protocolo
#11	AnnotatorNotes T13	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T14	DISO 858 876	enfermedad crónica
#12	AnnotatorNotes T14	C0008679; Chronic disease; Disease or Syndrome
T15	ANAT 888 907	sistema inmunitario
#13	AnnotatorNotes T15	C0020962; Immune system; Body System | C1305754; Entire immune system; Body System
T16	PROC 1211 1219	tratados
#14	AnnotatorNotes T16	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T17	DISO 931 960	síndrome de inmunodeficiencia
#15	AnnotatorNotes T17	C0021051; Immunologic Deficiency Syndromes; Disease or Syndrome
T18	DISO 985 995	malignidad
#16	AnnotatorNotes T18	C0006826; Malignant Neoplasms; Neoplastic Process
T19	DISO 1012 1023	infecciones
#17	AnnotatorNotes T19	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T20	PROC 1079 1090	tratamiento
#18	AnnotatorNotes T20	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T21	DISO 1109 1119	enfermedad
#19	AnnotatorNotes T21	C0012634; Disease; Disease or Syndrome
T22	CHEM 1159 1181	acetato de glatiramero
#20	AnnotatorNotes T22	C0289884; glatiramer acetate; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T23	CHEM 1225 1240	Interferón-beta
T24	CHEM 1243 1265	acetato de glatirámero
#21	AnnotatorNotes T24	C0289884; glatiramer acetate; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T25	PROC 1285 1299	aleatorización
#22	AnnotatorNotes T25	C0034656; Randomization; Research Activity
T26	CHEM 1301 1312	Natalizumab
#23	AnnotatorNotes T26	C1172734; natalizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T27	PROC 1341 1355	aleatorización
#24	AnnotatorNotes T27	C0034656; Randomization; Research Activity
T28	CHEM 1357 1367	Fingolimod
#25	AnnotatorNotes T28	C1699926; fingolimod; Immunologic Factor · Organic Chemical · Pharmacologic Substance
T29	PROC 1396 1410	aleatorización
#26	AnnotatorNotes T29	C0034656; Randomization; Research Activity
T30	CHEM 1412 1437	Fármacos inmunosupresores
#27	AnnotatorNotes T30	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T31	CHEM 1447 1458	azatioprina
#28	AnnotatorNotes T31	C0004482; azathioprine; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance
T32	CHEM 1460 1471	metotrexato
#29	AnnotatorNotes T32	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T33	PROC 1501 1515	aleatorización
#30	AnnotatorNotes T33	C0034656; Randomization; Research Activity
T34	CHEM 1518 1527	Rituximab
#31	AnnotatorNotes T34	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T35	PROC 1556 1570	aleatorización
#32	AnnotatorNotes T35	C0034656; Randomization; Research Activity
T36	CHEM 1572 1586	Ciclofosfamida
#33	AnnotatorNotes T36	C0010583; cyclophosphamide; Organic Chemical · Pharmacologic Substance
T37	CHEM 1588 1600	mitoxantrona
#34	AnnotatorNotes T37	C0026259; mitoxantrone; Organic Chemical · Pharmacologic Substance
T38	CHEM 1604 1615	alemtuzumab
#35	AnnotatorNotes T38	C0383429; alemtuzumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T39	PROC 1671 1680	protocolo
#36	AnnotatorNotes T39	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T40	PROC 86 92	tratar
#37	AnnotatorNotes T40	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T41	DISO 610 612	EM
#38	AnnotatorNotes T41	C0026769; Multiple Sclerosis; Disease or Syndrome
T42	DISO 919 921	EM
#39	AnnotatorNotes T42	C0026769; Multiple Sclerosis; Disease or Syndrome
T43	CHEM 366 372	AIN457
#40	AnnotatorNotes T43	C3179548; AIN 457; Amino Acid, Peptide, or Protein · Immunologic Factor
T44	CHEM 74 80	AIN457
#41	AnnotatorNotes T44	C3179548; AIN 457; Amino Acid, Peptide, or Protein · Immunologic Factor
T45	Date 13 17	2012
T46	LIVB 93 102	pacientes
#42	AnnotatorNotes T46	C0030705; Patients; Patient or Disabled Group
T47	LIVB 390 399	pacientes
#43	AnnotatorNotes T47	C0030705; Patients; Patient or Disabled Group
T48	Date 676 684	reciente
T49	Neg_cue 730 732	no
T50	Duration 733 749	mayor de 10 años
T51	LIVB 840 849	Pacientes
#44	AnnotatorNotes T51	C0030705; Patients; Patient or Disabled Group
T52	Duration 869 876	crónica
#45	AnnotatorNotes T52	C0205191; chronic; Temporal Concept
T53	LIVB 998 1007	Pacientes
#46	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	LIVB 1034 1043	Pacientes
#47	AnnotatorNotes T54	C0030705; Patients; Patient or Disabled Group
T55	Neg_cue 1121 1140	con la excepción de
T56	LIVB 1186 1195	Pacientes
#48	AnnotatorNotes T56	C0030705; Patients; Patient or Disabled Group
T57	Duration 1316 1327	los 6 meses
T58	Duration 1371 1382	los 3 meses
T59	Duration 1476 1487	los 6 meses
T60	Duration 1532 1542	los 2 años
T62	Duration 1269 1275	el mes
T63	Date 1619 1636	cualquier momento
T61	Neg_cue 908 918	distinta a
A1	Assertion T50 Negated
A2	Assertion T10 Negated
A3	Assertion T22 Negated
A4	Status T18 History_of
A5	Status T3 History_of
A6	Status T20 History_of
A7	Status T16 History_of
A8	Status T23 History_of
A9	Status T24 History_of
A10	Status T26 History_of
A11	Status T28 History_of
A12	Status T30 History_of
A13	Status T31 History_of
A14	Status T32 History_of
A15	Status T34 History_of
A16	Status T36 History_of
A17	Status T37 History_of
A18	Status T38 History_of
A19	Assertion T42 Negated
A20	Status T17 History_of
#49	AnnotatorNotes T2	C0282460; Phase 2 Clinical Trials; Research Activity + C1096776; Multicenter Study; Research Activity + C0206034; Clinical Trials, Randomized; Research Activity + C0013072; Double-Blind Method; Research Activity + C2826345; Parallel Study; Research Activity  + C0599724; placebo controlled study; Research Activity · Intellectual Product 
#50	AnnotatorNotes T8	C0751967; Multiple Sclerosis, Relapsing-Remitting; Disease or Syndrome
#51	AnnotatorNotes T23	C0015980; interferon-beta; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#52	AnnotatorNotes T48	C0332185; Recent; Temporal Concept
R1	Used_for Arg1:T44 Arg2:T40	
R2	Experiences Arg1:T46 Arg2:T44	
R3	Experiences Arg1:T46 Arg2:T1	
T64	Quantifier_or_Qualifier 127 147	que cursa con brotes
#53	AnnotatorNotes T64	C0205336; Relapsing course; Temporal Concept
R4	Has_Quantifier_or_Qualifier Arg1:T1 Arg2:T64	
T65	Quantifier_or_Qualifier 424 444	que cursa con brotes
#54	AnnotatorNotes T65	C0205336; Relapsing course; Temporal Concept
R5	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T65	
R6	Experiences Arg1:T47 Arg2:T6	
R7	Experiences Arg1:T47 Arg2:T5	
R8	Experiences Arg1:T47 Arg2:T43	
T66	Quantifier_or_Qualifier 489 499	con brotes
#55	AnnotatorNotes T66	C0205336; Relapsing course; Temporal Concept
R9	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T66	
T67	CONC 666 675	actividad
#56	AnnotatorNotes T67	C0679217; Active State; Idea or Concept
R10	Overlap Arg1:T67 Arg2:T48	
R11	Has_Duration_or_Interval Arg1:T12 Arg2:T50	
R12	Negation Arg1:T49 Arg2:T50	
T68	CONC 752 756	EDSS
#57	AnnotatorNotes T68	C3830336; EDSS - Expanded Disability Score; Intellectual Product
T69	Result_or_Value 757 768	entre 0 y 5
R13	Has_Result_or_Value Arg1:T68 Arg2:T69	
R14	Has_Duration_or_Interval Arg1:T14 Arg2:T52	
R15	Location_of Arg1:T15 Arg2:T14	
R16	Experiences Arg1:T51 Arg2:T14	
T70	Quantifier_or_Qualifier 877 883	activa
#58	AnnotatorNotes T70	C0679217; Active State; Idea or Concept
R17	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T70	
R18	Negation Arg1:T61 Arg2:T42	
R19	Experiences Arg1:T51 Arg2:T17	
R20	Experiences Arg1:T51 Arg2:T42	
R21	Location_of Arg1:T15 Arg2:T17	
R22	Experiences Arg1:T53 Arg2:T19	
T71	Quantifier_or_Qualifier 1024 1031	activas
#59	AnnotatorNotes T71	C0679217; Active State; Idea or Concept
R23	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T71	
T72	Quantifier_or_Qualifier 1069 1078	más de un
R24	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T72	
R25	Experiences Arg1:T54 Arg2:T3	
R26	Experiences Arg1:T54 Arg2:T20	
T73	Quantifier_or_Qualifier 1091 1119	modificador de la enfermedad
R27	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T73	
R28	Experiences Arg1:T54 Arg2:T21	
R29	Experiences Arg1:T54 Arg2:T10	
R30	Negation Arg1:T55 Arg2:T10	
R31	Combined_with Arg1:T10 Arg2:T22	
R32	Used_for Arg1:T23 Arg2:T16	
R33	Used_for Arg1:T24 Arg2:T16	
R34	Experiences Arg1:T56 Arg2:T16	
R35	Overlap Arg1:T24 Arg2:T62	
R36	Overlap Arg1:T23 Arg2:T62	
R37	Before Arg1:T26 Arg2:T27	
R39	Experiences Arg1:T56 Arg2:T26	
R40	Overlap Arg1:T26 Arg2:T57	
R41	Overlap Arg1:T28 Arg2:T58	
R42	Before Arg1:T28 Arg2:T29	
R43	Experiences Arg1:T56 Arg2:T28	
R44	Experiences Arg1:T56 Arg2:T30	
R45	Experiences Arg1:T56 Arg2:T31	
R46	Experiences Arg1:T56 Arg2:T32	
R47	Before Arg1:T32 Arg2:T33	
R48	Before Arg1:T31 Arg2:T33	
R49	Before Arg1:T30 Arg2:T33	
R50	Overlap Arg1:T32 Arg2:T59	
R51	Overlap Arg1:T31 Arg2:T59	
R52	Overlap Arg1:T30 Arg2:T59	
R53	Overlap Arg1:T34 Arg2:T60	
R54	Before Arg1:T34 Arg2:T35	
R55	Experiences Arg1:T56 Arg2:T34	
R56	Overlap Arg1:T38 Arg2:T63	
R57	Overlap Arg1:T37 Arg2:T63	
R58	Overlap Arg1:T36 Arg2:T63	
R59	Experiences Arg1:T56 Arg2:T36	
R60	Experiences Arg1:T56 Arg2:T37	
R61	Experiences Arg1:T56 Arg2:T38	
R62	Before Arg1:T24 Arg2:T25	
R63	Before Arg1:T23 Arg2:T25	
A21	Experiencer T46 Patient
A22	Experiencer T47 Patient
A23	Experiencer T51 Patient
A24	Experiencer T53 Patient
A25	Experiencer T54 Patient
A26	Experiencer T56 Patient
